Key result
Plasma log NT-proBNP levels ≥ 6.0661 predicted in-hospital mortality with 98.2% sensitivity and 88.9% specificity in patients with acute ischemic stroke.
Why the study?
Does plasma NT-proBNP level predict in-hospital mortality in patients with acute ischemic stroke?
Cohort (n=74)
No
Does plasma NT-proBNP level predict in-hospital mortality in patients with acute ischemic stroke?
Effect estimate: AUC 0.979 (95% CI 0.914-0.998)
p-value: p=0.0001
Plasma NT-proBNP levels, particularly at day 7, are highly sensitive and specific predictors of in-hospital mortality in patients with acute ischemic stroke.
May inform mortality risk stratification in acute ischemic stroke; hypothesis-generating and requires prospective validation before clinical adoption.
BACKGROUND: Sparse published data are available regarding the prognostic importance of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with acute ischemic stroke. MATERIALS AND METHODS: We prospectively studied 74 consecutive patients presenting with acute ischemic stroke within 24 hours of onset. All of them underwent laboratory and imaging evaluation and were treated as per guidelines. In all subjects, plasma NT-proBNP levels were measured at initial admission and again on day 7. RESULTS: Their mean age was 54 ± 13.5years; there were 49 males; 18 (24%) patients died during the hospital stay. A statistically significant negative correlation between log NT-proBNP and Glasgow coma scale (GCS) score (P < 0.001); and a significant positive correlation between log NT-proBNP and National Institutes of Health Stroke Scale (NIHSS) score (P < 0.001) were observed. Baseline log NT-proBNP levels were higher among non-survivors compared with survivors (6.7 ± 0.47 vs. 5.37 ± 0.62; P = 0.06); day 7 log NT-proBNP levels were significantly higher in non-survivors compared with survivors (7.3 ± 0.26 vs. 4.5 ± 0.4; P = 0.000). In survivors, there was a statistically significant decline in log NT-proBNP levels from baseline to day 7 (5.3710 ± 0.620 vs. 4.5320 ± 0.451; P < 0.001). In contrast, among non-survivors, log NT-proBNP levels showed a statistically significant increase from baseline to day 7 (4.5322 ± 0.451 vs. 7.2992 ± 0.263; P < 0.001). On receiver operator characteristic curve (ROC) analysis, at a cut-off value of ≥ 6.0661, log NT-proBNP had a sensitivity and specificity of 98.2 and 88.9, respectively, in predicting death. CONCLUSIONS: Plasma log NT-pro-BNP level appears to be a useful biological marker for predicting in-hospital mortality inpatients presenting with acute ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Naveen et al. (2015) conducted a cohort in Acute ischemic stroke (n=74). Plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) vs. Low NT-proBNP levels was evaluated on In-hospital mortality (AUC 0.979, 95% CI 0.914-0.998, p=0.0001). Plasma log NT-proBNP levels ≥ 6.0661 predicted in-hospital mortality with 98.2% sensitivity and 88.9% specificity in patients with acute ischemic stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: